|

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

RECRUITINGN/ASponsored by University of Tennessee
Actively Recruiting
PhaseN/A
SponsorUniversity of Tennessee
Started2018-06-19
Est. completion2019-06-18
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT03686709

Summary

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
* Must be able to schedule and tolerate additional PET/CT imaging following therapy
* Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.

Exclusion Criteria:

* Patients that are not candidates for Y90 radioembolization therapy
* Patients that cannot tolerate additional imaging procedures following therapy
* Patients that cannot tolerate the additional blood draws required for this study
* Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study

Conditions5

CancerHepatocellular CarcinomaLiver CancerLiver DiseaseRadiation Exposure

Locations1 site

University of Tennessee Medical Center
Knoxville, Tennessee, 37920
Melissa Weaver865-305-6181mweaver@utmck.edu

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.